Meeting
2014 Genitourinary Cancers Symposium
Evaluation of the Oncotype DX genomic prostate score for risk stratification in prostate cancer patients considered candidiates for active surveilance.
Authors
Ganesh K Kartha
Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH
Ganesh K Kartha , Yaw Nyame , Eric A. Klein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 122)
DOI
10.1200/jco.2014.32.4_suppl.122
Abstract #
122
Poster Bd #
G21
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Treatment decisions and outcomes for NCCN favorable intermediate-risk prostate cancer patients after receiving the 17-gene genomic prostate cancer score result.
First Author: Eric Margolis
Poster
2023 ASCO Genitourinary Cancers Symposium
The impact of genomic biomarkers on a validated clinical risk prediction model for upgrading/upstaging among men with low-risk prostate cancer.
First Author: Avery Braun
Poster
2021 Genitourinary Cancers Symposium
Genomic analysis for active surveillance to predict upstaging after prostatectomy.
First Author: Andrea Quinn
Poster
2023 ASCO Genitourinary Cancers Symposium
Geographic variation of decipher genomic classifier in patients with early prostate cancer.
First Author: Daniel Keizman